JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

Kodu・Aktsiate loetelu・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Suletud

SektorTervishoid

20.05 -1.33

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.93

Max

21.17

Põhinäitajad
By Trading Economics
Sissetulek	11M -61M
Müük	7.9M 46M
Kasumimarginaal	-132.36
Töötajad	270
EBITDA	6.3M -58M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+82.16% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	2. märts 2026

Turustatistika
By TradingEconomics
Turukapital	726M 1.9B
Eelmine avamishind	21.38
Eelmine sulgemishind	20.05

Uudiste sentiment

By Acuity

50%

147 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

9.91 / 14.15 Toetus ja vastupanu

Syndax Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. veebr 2026, 23:57 UTC

Tulu

Naver Has Record Year Despite Weaker Final Quarter

5. veebr 2026, 23:45 UTC

Kuumad aktsiad

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

5. veebr 2026, 22:26 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

5. veebr 2026, 22:00 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

5. veebr 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

5. veebr 2026, 23:47 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

5. veebr 2026, 23:43 UTC

Market Talk

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

5. veebr 2026, 23:37 UTC

Market Talk

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

5. veebr 2026, 23:20 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

5. veebr 2026, 23:11 UTC

Market Talk

Amazon CEO Confident in Return on $200B Investment -- Market Talk

5. veebr 2026, 23:09 UTC

Tulu

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

5. veebr 2026, 23:08 UTC

Tulu

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

5. veebr 2026, 23:07 UTC

Tulu

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

5. veebr 2026, 23:03 UTC

Market Talk

Tulu

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

5. veebr 2026, 23:03 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

5. veebr 2026, 23:00 UTC

Tulu

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

5. veebr 2026, 23:00 UTC

Tulu

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

5. veebr 2026, 22:59 UTC

Tulu

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

5. veebr 2026, 22:59 UTC

Tulu

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

5. veebr 2026, 22:52 UTC

Tulu

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

5. veebr 2026, 22:45 UTC

Tulu

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

5. veebr 2026, 22:37 UTC

Market Talk

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

5. veebr 2026, 22:11 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

5. veebr 2026, 22:03 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

5. veebr 2026, 22:01 UTC

Tulu

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

5. veebr 2026, 21:59 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

5. veebr 2026, 21:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

5. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

5. veebr 2026, 21:49 UTC

Tulu

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

5. veebr 2026, 21:45 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Võrdlus sarnastega

Hinnamuutus

Syndax Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

82.16% tõus

12 kuu keskmine prognoos

Keskmine 38.71 USD 82.16%

Kõrge 56 USD

Madal 28 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Syndax Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Syndax Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

9.91 / 14.15Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

147 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.